Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

Author： Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.4, 2013-04, pp. : 405-414

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 139, Iss. 10, 2016-11 ,pp. : 2336-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite

T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 3, 2017-11 ,pp. : 216-222

Bentham Science Publishers

Access to resources Recommend Favorite

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 642-651

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite